Notícias e Atividades da Dementia Discovery Fund

Dementia Discovery Fund pertence à SV Health Investors. SV Health Investors tem presença direta em 2 países.

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Dementia Discovery Fund

• Kate Bingham, Managing Partner
• James Costine, Chief Financial Officer
• Mike Ross, Senior Partner

Recentes movimentos de executivos em SV Health Investors

• A.J. Rossi antes Principal, Healthcare Growth-Buyout, foi promovido a Partner, Healthcare Growth-Buyout  (Notícia publicada em 23 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Dementia Discovery Fund.

SV Health Investors possui 1.573 concorrentes concorrentes BlackRock (Estados Unidos), KKR (Estados Unidos) e Vanguard (Estados Unidos).

Popular M&A news in Fundo

• Seven2 has announced the acquisition of HRK Lunis  (publicado em 3 de abril de 2025).
• Fluent adquiriu RIV Capital (publicado em 20 de dezembro de 2024).
• RIV Capital and Fluent have announced they will merge  (publicado em 14 de outubro de 2024)..

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director da General Catalyst Partners

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de Dementia Discovery Fund

• Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets - SV Health Investors
• Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases - SV Health Investors
• Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases - SV Health Investors
• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - SV Health Investors
• News - SV Health Investors
• Endlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease - SV Health Investors
• Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 - SV Health Investors
• British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2 - SV Health Investors
• Nitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease - SV Health Investors
• Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board - SV Health Investors
• View more press releases Close

Redes sociais sobre Dementia Discovery Fund

• Dementia Discovery Fund na Wikipedia, Google News e Yahoo Finance
• Dementia Discovery Fund na LinkedIn, Twitter e YouTube